Gilead Sciences acquires Arcellx

Gilead Sciences is set to fully acquire Arcellx, Inc. in a transaction valued at $7.8 billion, aimed at expanding its cell therapy portfolio. Announced as a definitive agreement, the terms stipulate a cash payment of $115 per share along with a contingent value right of $5 per share. This acquisition will provide Gilead with complete control over Arcellx's operations and its pipelines, most notably anitocabtagene autoleucel (anito-cel), a CAR T-cell therapy targeted at multiple myeloma.

The acquisition significantly shifts Gilead's stake in the CAR T-cell sector, particularly enhancing its development and commercialization capacity for anito-cel. Arcellx and Gilead initially partnered in 2022 to co-develop anito-cel, and this acquisition eliminates previous profit-sharing, milestone payments, and royalties between the two companies. Anito-cel is currently under FDA review as a potential fourth-line treatment for relapsed or refractory multiple myeloma, with a decision expected by December 2026. Clinical trials have highlighted promising outcomes, addressing critical issues of safety and efficacy that limit current therapies for this challenging cancer subset.

Beyond anito-cel, Arcellx's D-Domain CAR technology platform offers Gilead a strategic advantage with advanced proprietary target-binding domains. This technology could advance further innovations in both CAR T-cell and bispecific therapies, potentially broadening Gilead’s therapeutic impact across oncology and inflammation. The inclusion of Arcellx's D-domain BCMA binder is anticipated to enhance Gilead’s existing in vivo cell therapy initiatives.

In a fiercely competitive landscape, this acquisition gives Gilead a considerable edge. With the biotechnology sector driven by advancements in personalized medicine, gaining control of anito-cel aligns with a broader industry trend of companies seeking to bolster their portfolios with innovative cell and gene therapies. The deal, providing a 68% premium to Arcellx’s average share price as of February 2026, underscores Gilead’s ambition within specialty biotechnologies.

The transaction awaits regulatory clearance and the tender of the remaining Arcellx shares. With both companies’ boards having already greenlighted the deal, Gilead aims to finalize the acquisition by the second quarter of 2026. Should anito-cel receive FDA approval, the acquisition is projected to enhance Gilead's earnings per share beginning in 2028. This development marks a deliberate move to solidify its presence in the oncology sector and sustain long-term growth amidst a shifting regulatory and competitive landscape.